Novo Nordisk's insulin aspart franchise is a ... having a biosimilar option for their rapid-acting insulin injection can truly make a difference, as biosimilar products have the potential to ...

Merilog, made by Sanofi-Aventis, is a rapid-acting insulin biosimilar (similar to Novo Nordisk’s Novolog) that helps control blood sugar spikes when taken five to 10 minutes before a meal.

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

March 4 (Reuters) - South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority ...

In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast. In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering ...